Annovis Bio’s (ANVS) “Hold” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their hold rating on shares of Annovis Bio (NYSE:ANVS) in a research report report published on Monday morning, Marketbeat reports.

Several other analysts also recently weighed in on ANVS. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Annovis Bio in a report on Monday, November 11th. Maxim Group upgraded Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Friday, October 25th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.40.

Annovis Bio Trading Up 2.4 %

NYSE:ANVS opened at $2.58 on Monday. Annovis Bio has a twelve month low of $2.44 and a twelve month high of $20.00. The company has a market cap of $36.73 million, a price-to-earnings ratio of -0.58 and a beta of 1.63. The stock has a fifty day simple moving average of $4.74 and a 200-day simple moving average of $7.04.

Hedge Funds Weigh In On Annovis Bio

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in Annovis Bio by 30.0% in the third quarter. Geode Capital Management LLC now owns 99,114 shares of the company’s stock worth $799,000 after purchasing an additional 22,881 shares in the last quarter. Merit Financial Group LLC raised its holdings in Annovis Bio by 269.0% in the fourth quarter. Merit Financial Group LLC now owns 98,516 shares of the company’s stock worth $496,000 after purchasing an additional 71,816 shares in the last quarter. Quest Partners LLC bought a new position in Annovis Bio in the third quarter worth about $371,000. State Street Corp raised its holdings in Annovis Bio by 23.7% in the third quarter. State Street Corp now owns 36,035 shares of the company’s stock worth $290,000 after purchasing an additional 6,900 shares in the last quarter. Finally, Greenwich Wealth Management LLC raised its holdings in Annovis Bio by 93.9% in the fourth quarter. Greenwich Wealth Management LLC now owns 31,951 shares of the company’s stock worth $161,000 after purchasing an additional 15,476 shares in the last quarter. 15.83% of the stock is currently owned by institutional investors.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.